LONDON, Nov 22 (Reuters) – Biogen Idec has won
regulatory protection for its top-selling multiple sclerosis
drug Tecfidera in Europe, paving the way for its launch in
markets that could account for a large proportion of future
The European Medicines Agency said on Friday it had granted
the oral medicine a “new active substance” (NAS) designation,
securing Biogen 10 years protection through data exclusivity
that will stop generic firms from launching copycat versions.
LONDON (Reuters) – Novartis is hot on the heels of Pfizer in developing a promising new type of breast cancer drug that analysts believe could generate billions of dollars in annual sales.
The Swiss drugmaker, which has previously kept its research program under wraps, revealed on Friday that its experimental pill LEE011 was set to enter final-stage Phase III clinical trials next month.
LONDON (Reuters) – Europe’s main drugs regulator has found no new safety issues linked to Roche medicines after an investigation into the Swiss drugmaker, which was rapped last year for lax drug-safety reporting.
The European Medicines Agency (EMA) launched a probe into Roche in June 2012 after a routine inspection found it had failed to properly assess tens of thousands of cases of possible adverse drug reactions.
LONDON, Nov 15 (Reuters) – Europe faces a growing threat
from superbugs that are resistant to a powerful, last-resort
class of antibiotics known as carbapenems, the EU’s disease
monitoring agency said on Friday.
It is the latest in a series of warnings about antibiotic
resistance from healthcare authorities around the world who fear
that in future simple infections may no longer respond to
LONDON (Reuters) – Humans first made dogs their best friends in prehistoric Europe, where groups of hunter-gathers learnt to tame dangerous wolves into companions between 19,000 and 32,000 years ago, scientists said on Thursday.
The new research, based on analysis of DNA fragments from fossils of ancient wolves and dogs, confounds earlier theories that dogs were originally domesticated in the Middle East or East Asia.
KALUNDBORG, Denmark (Reuters) – Steam rises from pipes at a giant industrial complex on the edge of the Baltic Sea whose success is a testament to the world’s diabetes and obesity epidemic.
Novo Nordisk’s Kalundborg factory, 100 km west of Copenhagen, makes half the planet’s insulin for diabetics, putting it on a list of global sites the United States sees as vital to its interests, according to a WikiLeaks cable in 2010.
KALUNDBORG, Denmark, Nov 14 (Reuters) – Steam rises from
pipes at a giant industrial complex on the edge of the Baltic
Sea whose success is a testament to the world’s diabetes and
Novo Nordisk’s Kalundborg factory, 100 km west of
Copenhagen, makes half the planet’s insulin for diabetics,
putting it on a list of global sites the United States sees as
vital to its interests, according to a WikiLeaks cable in 2010.
NEW YORK/LONDON (Reuters) – The first human tests of experimental vaccines against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, has produced protective antibodies in the vast majority of recipients.
Encouraging results in early-stage trials were announced for separate vaccines from Swiss drugmaker Novartis and Novavax, a biotech company based in Rockville, Maryland.